GLP1_NEW
Exenatide extended release and dapagliflozin injection
DAPAEXEN_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Dapagliflozin | MD -0.58 (-1.53 to 0.53) | 0.83 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.43 (-1.98 to -0.85) | 0.89 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Exenatide extended release injection | MD -0.37 (-1.30 to 0.61) | 0.90 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.15 (1.31 to 14.21) | 0.63 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.31 (-8.65 to -1.82) | 0.88 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.38 (-9.86 to -1.02) | 0.74 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.00 (0.48 to 2.05) | 0.50 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.89 (0.32 to 2.38) | 0.63 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.19 (0.35 to 3.76) | 0.62 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.14 (0.49 to 2.66) | 0.58 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.78 (-1.60 to 0.13) | 0.89 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD -0.03 (-0.23 to 0.17) | 0.45 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.62 (0.01 to 52.19) | 0.56 |